Datasets:
docs: shopfront moved to dataengineered.io
Browse files
README.md
CHANGED
|
@@ -1,73 +1,73 @@
|
|
| 1 |
-
---
|
| 2 |
-
license: cc-by-nc-4.0
|
| 3 |
-
pretty_name: "CSA — Clinical-Stage Asset Intelligence (Free Sample)"
|
| 4 |
-
task_categories:
|
| 5 |
-
- tabular-classification
|
| 6 |
-
tags:
|
| 7 |
-
- biotech
|
| 8 |
-
- clinical-trials
|
| 9 |
-
- finance
|
| 10 |
-
- pharmaceuticals
|
| 11 |
-
- catalyst-calendar
|
| 12 |
-
- healthcare
|
| 13 |
-
size_categories:
|
| 14 |
-
- n<1K
|
| 15 |
-
configs:
|
| 16 |
-
- config_name: catalyst_calendar
|
| 17 |
-
data_files: catalyst_calendar_sample.csv
|
| 18 |
-
default: true
|
| 19 |
-
- config_name: asset_master
|
| 20 |
-
data_files: asset_master_sample.csv
|
| 21 |
-
---
|
| 22 |
-
|
| 23 |
-
# CSA — Clinical-Stage Asset Intelligence · Free Sample
|
| 24 |
-
|
| 25 |
-
**Clinical trials, FDA, and SEC — linked to the drug asset and the listed sponsor, with a
|
| 26 |
-
forward catalyst calendar.** This is a free 150-row sample of the nearest-term
|
| 27 |
-
catalysts; the full snapshot carries **2,103 forward catalysts** across
|
| 28 |
-
**139 listed sponsors** and **1,841 resolved assets**.
|
| 29 |
-
|
| 30 |
-
> **Data, not investment advice.** CSA is information, not a recommendation to buy, sell,
|
| 31 |
-
> or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates)
|
| 32 |
-
> routinely slip and are graded by confidence — verify anything material against the
|
| 33 |
-
> `source_url` on each row.
|
| 34 |
-
|
| 35 |
-
## What's inside
|
| 36 |
-
|
| 37 |
-
| File | Rows | What it is |
|
| 38 |
-
| :-- | :-- | :-- |
|
| 39 |
-
| `catalyst_calendar_sample.csv` | 150 | Nearest-term forward catalysts (2026-07-18 → 2027-09-01), 108 assets, 50 sponsors. |
|
| 40 |
-
| `asset_master_sample.csv` | 464 | The asset ↔ trial ↔ sponsor ↔ ticker rows behind them. |
|
| 41 |
-
| `*_sample.json` | — | The same tables as records-oriented JSON. |
|
| 42 |
-
|
| 43 |
-
### `catalyst_calendar_sample.csv`
|
| 44 |
-
`event_date` · `ticker` · `asset` · `event_type` (PDUFA / READOUT / …) · `event_window`
|
| 45 |
-
· `date_precision` · `confidence` · `source` (sec_8k / clinicaltrials) · `nct_id` · `source_url`.
|
| 46 |
-
|
| 47 |
-
### `asset_master_sample.csv`
|
| 48 |
-
`asset` · `nct_id` · `phase` · `status` · `primary_completion` · `conditions` · `arm_role`
|
| 49 |
-
· `sponsor_raw` · `company_name` · `ticker`.
|
| 50 |
-
|
| 51 |
-
## How it's built
|
| 52 |
-
|
| 53 |
-
- **Active-moiety resolution** keys each asset to its FDA-registered UNII set (GSRS), not
|
| 54 |
-
fuzzy names — audited to **zero cross-molecule merges**.
|
| 55 |
-
- **Sponsor → listed ticker** through acquisitions, to the primary US listing.
|
| 56 |
-
- **Dual-channel catalysts**: SEC 8-K disclosure text + active late-phase
|
| 57 |
-
ClinicalTrials.gov protocol readouts. Every row carries its source.
|
| 58 |
-
|
| 59 |
-
Sample scope: active, industry-sponsored, Phase 3 trials in cardiometabolic, oncology and
|
| 60 |
-
immunology. Asset names are normalized for readability; the sample is curated to
|
| 61 |
-
clinical-stage, single-sponsor assets.
|
| 62 |
-
|
| 63 |
-
## Sources & license
|
| 64 |
-
|
| 65 |
-
All primary sources are U.S. Government / public domain: **ClinicalTrials.gov**,
|
| 66 |
-
**openFDA**, **SEC EDGAR**, **GSRS/UNII**. This sample is released under **CC-BY-NC-4.0**
|
| 67 |
-
(free to use and share with attribution, not to re-sell). See `SAMPLE_LICENSE.md`.
|
| 68 |
-
|
| 69 |
-
## Get the full dataset
|
| 70 |
-
|
| 71 |
-
The complete, commercially-licensed snapshot (all 2,103 catalysts, CSV +
|
| 72 |
-
JSON, monthly editions + delta feed) → **https://csa
|
| 73 |
-
· code: **https://github.com/CSA-pub/CSA-public** · contact: **https://csa
|
|
|
|
| 1 |
+
---
|
| 2 |
+
license: cc-by-nc-4.0
|
| 3 |
+
pretty_name: "CSA — Clinical-Stage Asset Intelligence (Free Sample)"
|
| 4 |
+
task_categories:
|
| 5 |
+
- tabular-classification
|
| 6 |
+
tags:
|
| 7 |
+
- biotech
|
| 8 |
+
- clinical-trials
|
| 9 |
+
- finance
|
| 10 |
+
- pharmaceuticals
|
| 11 |
+
- catalyst-calendar
|
| 12 |
+
- healthcare
|
| 13 |
+
size_categories:
|
| 14 |
+
- n<1K
|
| 15 |
+
configs:
|
| 16 |
+
- config_name: catalyst_calendar
|
| 17 |
+
data_files: catalyst_calendar_sample.csv
|
| 18 |
+
default: true
|
| 19 |
+
- config_name: asset_master
|
| 20 |
+
data_files: asset_master_sample.csv
|
| 21 |
+
---
|
| 22 |
+
|
| 23 |
+
# CSA — Clinical-Stage Asset Intelligence · Free Sample
|
| 24 |
+
|
| 25 |
+
**Clinical trials, FDA, and SEC — linked to the drug asset and the listed sponsor, with a
|
| 26 |
+
forward catalyst calendar.** This is a free 150-row sample of the nearest-term
|
| 27 |
+
catalysts; the full snapshot carries **2,103 forward catalysts** across
|
| 28 |
+
**139 listed sponsors** and **1,841 resolved assets**.
|
| 29 |
+
|
| 30 |
+
> **Data, not investment advice.** CSA is information, not a recommendation to buy, sell,
|
| 31 |
+
> or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates)
|
| 32 |
+
> routinely slip and are graded by confidence — verify anything material against the
|
| 33 |
+
> `source_url` on each row.
|
| 34 |
+
|
| 35 |
+
## What's inside
|
| 36 |
+
|
| 37 |
+
| File | Rows | What it is |
|
| 38 |
+
| :-- | :-- | :-- |
|
| 39 |
+
| `catalyst_calendar_sample.csv` | 150 | Nearest-term forward catalysts (2026-07-18 → 2027-09-01), 108 assets, 50 sponsors. |
|
| 40 |
+
| `asset_master_sample.csv` | 464 | The asset ↔ trial ↔ sponsor ↔ ticker rows behind them. |
|
| 41 |
+
| `*_sample.json` | — | The same tables as records-oriented JSON. |
|
| 42 |
+
|
| 43 |
+
### `catalyst_calendar_sample.csv`
|
| 44 |
+
`event_date` · `ticker` · `asset` · `event_type` (PDUFA / READOUT / …) · `event_window`
|
| 45 |
+
· `date_precision` · `confidence` · `source` (sec_8k / clinicaltrials) · `nct_id` · `source_url`.
|
| 46 |
+
|
| 47 |
+
### `asset_master_sample.csv`
|
| 48 |
+
`asset` · `nct_id` · `phase` · `status` · `primary_completion` · `conditions` · `arm_role`
|
| 49 |
+
· `sponsor_raw` · `company_name` · `ticker`.
|
| 50 |
+
|
| 51 |
+
## How it's built
|
| 52 |
+
|
| 53 |
+
- **Active-moiety resolution** keys each asset to its FDA-registered UNII set (GSRS), not
|
| 54 |
+
fuzzy names — audited to **zero cross-molecule merges**.
|
| 55 |
+
- **Sponsor → listed ticker** through acquisitions, to the primary US listing.
|
| 56 |
+
- **Dual-channel catalysts**: SEC 8-K disclosure text + active late-phase
|
| 57 |
+
ClinicalTrials.gov protocol readouts. Every row carries its source.
|
| 58 |
+
|
| 59 |
+
Sample scope: active, industry-sponsored, Phase 3 trials in cardiometabolic, oncology and
|
| 60 |
+
immunology. Asset names are normalized for readability; the sample is curated to
|
| 61 |
+
clinical-stage, single-sponsor assets.
|
| 62 |
+
|
| 63 |
+
## Sources & license
|
| 64 |
+
|
| 65 |
+
All primary sources are U.S. Government / public domain: **ClinicalTrials.gov**,
|
| 66 |
+
**openFDA**, **SEC EDGAR**, **GSRS/UNII**. This sample is released under **CC-BY-NC-4.0**
|
| 67 |
+
(free to use and share with attribution, not to re-sell). See `SAMPLE_LICENSE.md`.
|
| 68 |
+
|
| 69 |
+
## Get the full dataset
|
| 70 |
+
|
| 71 |
+
The complete, commercially-licensed snapshot (all 2,103 catalysts, CSV +
|
| 72 |
+
JSON, monthly editions + delta feed) → **https://csa.dataengineered.io**
|
| 73 |
+
· code: **https://github.com/CSA-pub/CSA-public** · contact: **https://csa.dataengineered.io/#contact**
|